Optimization of stable liquid crystal nanoparticles for intranasal delivery

Conventional liquid crystal (LC) formulations have been studied for nasal drug delivery, but they often exhibit high viscosity and limited diffusion, reducing their suitability for nasal application. To improve this, liquid crystal nanoparticles (LCNPs) dispersed in an aqueous phase has been proposed. LCNPs (e.g., cubosomes/hexosomes) are lipid-based nanocarriers with internal nanostructured channels that can solubilize lipophilic drugs and provide sustained release, offering a strategy to enhance nasal retention and absorption. In this study, we develop a stable LCN-based intranasal delivery system for a BCS class II model drug based on design of experiment (DOE) approach.